ReviewViruses2022
A Review of HDV Infection.
Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 48 citations in OpenAlex.
- Promoting expertise knowledge sharing in paediatric virology: An update (Review).Experimental and therapeutic medicine · 2026Review
- Deubiquitinases in liver diseases: from mechanisms to targeted therapy.Science China. Life sciences · 2026Review
- Novel epitope-based diagnostic probes selected by phage display for the serological detection of HDVMemorias do Instituto Oswaldo Cruz · 2026Article
- Epidemiology of hepatitis D virus coinfection among HBsAg-positive individuals in Kermanshah, Western Iran.GMS hygiene and infection control · 2026Article
- Hepatitis C (HCV) and Hepatitis Delta (HDV) Viruses in a Teaching Hospital in Southern Italy: What Is the Epidemiological Situation in the Era of New Drugs?Pathogens (Basel, Switzerland) · 2025Observational
- Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.Virology journal · 2025Review
- The burden of viral hepatitis infection and mortality: Findings from a population-based study in Poland over 2009-2023.Clinical and experimental hepatology · 2025Article
- Diagnostic Accuracy of Plate-Based Digital PCR Assays for Simultaneous Quantitation of Hepatitis B and D Viral Loads in Patients' Serum.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Prevalence of Hepatitis D Virus Antibody Positivity in Chinese Patients with Chronic Hepatitis B Virus Infection.Journal of clinical and translational hepatology · 2025Article
- Article
- [Hepatocellular carcinoma (HCC)].Medecine tropicale et sante internationale · 2024Review
- Effect of Peg-IFN on the viral kinetics of patients with HDV infection treated with bulevirtide.JHEP reports : innovation in hepatology · 2024Article
- Insights into Immune Exhaustion in Chronic Hepatitis B: A Review of Checkpoint Receptor Expression.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Prevalence of Hepatitis D in People Living with HIV: A National Cross-Sectional Pilot Study.Viruses · 2024Article
- Hepatitis C Virus as a Possible Helper Virus in Human Hepatitis Delta Virus Infection.Viruses · 2024Article
- Hepatitis Delta Virus and Hepatocellular Carcinoma.Pathogens (Basel, Switzerland) · 2024Review
- Improving Access to Anti-HDV Testing: Development and Validation of an Affordable In-House ELISA Assay.ACS omega · 2024Article
- Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP.Nature communications · 2024Article
- Prevalence of HDV infections in Poland based on the experience of a single center in Silesia and literature research.Clinical and experimental hepatology · 2024Article
- Laboratory development of an RNA quantitative RT-PCR assay reporting in international units for hepatitis D virus.Frontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis D is the most severe viral hepatitis. Hepatitis D virus (HDV) has a very small RNA genome with unique biological properties. It requires for infection the presence of hepatitis B virus (HBV) and is transmitted parenterally, mainly by superinfection of HBsAg carriers who then develop chronic hepatitis D. HDV has been brought under control in high-income countries by the implementation of HBV vaccination, and the clinical pattern has changed to a chronic hepatitis D seen in ageing patients with advanced fibrotic disease; the disease remains a major health concern in developing countries of Africa and Asia. Every HBsAg-positive subject should be tested for HDV serum markers by reflex testing, independently of clinical status. Vaccination against HBV provides the best prophylaxis against hepatitis D. The only therapy available so far has been the poorly performing Interferon alfa; however, several new and promising therapeutic approaches are under study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.